Endocrine Abstracts

Introduction: Alemtuzumab is a monoclonal antibody targeting the CD52 glycoprotein, which is expressed by most mature leucocytes. In early relapsing-remitting multiple sclerosis (MS) alentuzumab effectively decreases relapse rate and disability progression. However, nearly 50% of the pacients treated with alentuzumab develop secondary autoimmune disorders, being Graves’ disease the most common. The development of thyroid eye disease is unusual.Aims ...

Objective: To study the characteristics of a cohort of patients with Graves’ orbitopathy (GO) as a self-audit prior to the creation of a multidisciplinary team for the global approach of these patients.Material and Methods: Retrospective study of patients with GO treated at the Endocrinology and Ophthalmology Services of a tertiary referral hospital (Virgen Macarena University Hospital, Seville, Andalusia, Spain) between 2018 and 2021. The following...

Objectives: To identify risk factors for the development of Graves’ Orbitopathy (GO) in patients with Relapsing Remitting Multiple Sclerosis (RRMS) treated with Alemtuzumab, as well as to analyze the clinical behavior of this entity based on a case series.Methods: Retrospective observational study with real-life data. Patients with RRMS who received at least one cycle of Alemtuzumab in the period 2014-2022 in aMS reference unit in Spain were include...